[Platelet aggregation inhibition with calcium dobesilate].

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Pathologically increased platelet aggregation is a risk factor for thrombotic events.
• Calcium dobesilate is a veno-active drug with potential antiplatelet properties.

Purpose of the Study:

• To evaluate the efficacy of different oral doses of calcium dobesilate in reducing spontaneous platelet aggregation.
• To compare the effects of 500 mg, 1000 mg, and 1500 mg calcium dobesilate against a placebo.

Main Methods:

• A randomized, placebo-controlled study involving 52 patients with pathologically increased platelet aggregation.
• Treatment duration was 4 days with varying oral doses of calcium dobesilate.
• Platelet aggregation was assessed using the PAT III method (Breddin).

Main Results:

• A significant reduction in platelet aggregation was observed with 1500 mg of calcium dobesilate compared to placebo.
• No significant difference in platelet aggregation was found with 500 mg or 1000 mg of calcium dobesilate versus placebo.
• The antiplatelet effect was dose-dependent.

Conclusions:

• High-dose calcium dobesilate (1500 mg) demonstrates significant efficacy in reducing pathological platelet aggregation.
• Lower doses of calcium dobesilate are not effective in altering spontaneous platelet aggregation.
• Calcium dobesilate may be a potential therapeutic agent for conditions characterized by hypercoagulability.